Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Pál, Gergely"'
Autor:
Lilla Nagy, Ferenc Béke, László Juhász, Tünde Kovács, Éva Juhász-Tóth, Tibor Docsa, Attila Tóth, Pál Gergely, László Somsák, Péter Bai
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0236081 (2020)
Type 2 diabetes mellitus (T2DM), one of the most common metabolic diseases, is characterized by insulin resistance and inadequate insulin secretion of β cells. Glycogen phosphorylase (GP) is the key enzyme in glycogen breakdown, and contributes to h
Externí odkaz:
https://doaj.org/article/ccd98b64c7e4413ca14929aa806fc085
Autor:
Csilla Szűcs Somogyi, Csaba Matta, Zsofia Foldvari, Tamás Juhász, Éva Katona, Ádám Roland Takács, Tibor Hajdú, Nóra Dobrosi, Pál Gergely, Róza Zákány
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 8, Pp 18412-18438 (2015)
Mature and developing chondrocytes exist in a microenvironment where mechanical load, changes of temperature, osmolarity and acidic pH may influence cellular metabolism. Polymodal Transient Receptor Potential Vanilloid (TRPV) receptors are environmen
Externí odkaz:
https://doaj.org/article/850d5cd9f6ba459f9d53ff9c7cf4a7af
Autor:
Tamás Juhász, Csaba Matta, Éva Katona, Csilla Somogyi, Roland Takács, Pál Gergely, László Csernoch, Gyorgy Panyi, Gábor Tóth, Dóra Reglődi, Andrea Tamás, Róza Zákány
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91541 (2014)
Pituitary adenylate cyclase activating polypeptide (PACAP) is an important neurotrophic factor influencing differentiation of neuronal elements and exerting protecting role during traumatic injuries or inflammatory processes of the central nervous sy
Externí odkaz:
https://doaj.org/article/2030a01e45954357a2a787cbaf4cc3ec
Autor:
Lilla Nagy, Tibor Docsa, Magdolna Szántó, Attila Brunyánszki, Csaba Hegedűs, Judit Márton, Bálint Kónya, László Virág, László Somsák, Pál Gergely, Péter Bai
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e69420 (2013)
Glycogen phosphorylase (GP) catalyzes the breakdown of glycogen and largely contributes to hepatic glucose production making GP inhibition an attractive target to modulate glucose levels in diabetes. Hereby we present the metabolic effects of a novel
Externí odkaz:
https://doaj.org/article/313a746639f7435f87eba45d50e39286
Autor:
Cédric Duret, Sophie Balzarin, Didier Tousch, Bálint Kónya, Michel Tournier, Pierre Petit, Pál Gergely, Paolo Larini, David Goyard, Jean-Pierre Praly, Jérémy Leroy, Tibor Docsa, Jacqueline Azay-Milhau, Patrick Maurel, Katalin Czifrák, Sébastien Vidal, Fanny Demontrond, László Somsák
Publikováno v:
Organic and Biomolecular Chemistry
Organic and Biomolecular Chemistry, Royal Society of Chemistry, 2020, 18 (5), pp.931-940. ⟨10.1039/C9OB01190K⟩
Organic and Biomolecular Chemistry, Royal Society of Chemistry, 2020, 18 (5), pp.931-940. ⟨10.1039/c9ob01190k⟩
Organic & Biomolecular Chemistry
Organic & Biomolecular Chemistry, 2020, 18 (5), pp.931-940. ⟨10.1039/C9OB01190K⟩
Organic and Biomolecular Chemistry, Royal Society of Chemistry, 2020, 18 (5), pp.931-940. ⟨10.1039/C9OB01190K⟩
Organic and Biomolecular Chemistry, Royal Society of Chemistry, 2020, 18 (5), pp.931-940. ⟨10.1039/c9ob01190k⟩
Organic & Biomolecular Chemistry
Organic & Biomolecular Chemistry, 2020, 18 (5), pp.931-940. ⟨10.1039/C9OB01190K⟩
International audience; The design of glycogen phosphorylase (GP) inhibitors targeting the catalytic site of the enzyme is a promising strategy for a better control of hyperglycaemia in the context of type 2 diabetes. Glucopyranosylidene-spiro-hetero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbaea3c59453ca87bdeda8c62fcedb61
https://hal.univ-grenoble-alpes.fr/hal-02942989/file/Fulltext_Vidal_Revision.pdf
https://hal.univ-grenoble-alpes.fr/hal-02942989/file/Fulltext_Vidal_Revision.pdf
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e35595 (2012)
Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 (EBP50) is a phosphorylatable PDZ domain-containing adaptor protein that is abundantly expressed in epithelium but was not yet studied in the endothelium. We report unusual nuclear localization of
Externí odkaz:
https://doaj.org/article/2c1cbbafd6c24ee885f30334ce7df6cd
Autor:
Éva Bokor, Spyros E. Zographos, Georgios A Stravodimos, Anastassia L. Kantsadi, Tibor Docsa, László Somsák, Andrea Szakács, Efthimios Kyriakis, Theodora G.A. Solovou, Demetres D. Leonidas, Katalin E. Szabó, Csenge Koppány, Pál Gergely, Vassiliki T. Skamnaki
Publikováno v:
Journal of Medicinal Chemistry. 60:9251-9262
Aryl substituted 1-(β-d-glucosaminyl)-1,2,3-triazoles as well as C-β-d-glucosaminyl 1,2,4-triazoles and imidazoles were synthesized and tested as inhibitors against muscle and liver isoforms of glycogen phosphorylase (GP). While the N-β-d-glucosam
Autor:
Miklós Antal, Mónika Gönczi, Judit Márton, Lilla Nikoletta Nagy, Balázs Csóka, Pal Pacher, Tibor Docsa, Attila Tóth, András Vida, Éva Bokor, László Somsák, Sándor Kun, Péter Bai, Gréta Kis, Pál Gergely
Publikováno v:
British Journal of Pharmacology. 175:301-319
Background and Purpose Glycogen phosphorylase (GP) is the key enzyme for glycogen degradation. GP inhibitors (GPi-s) are glucose lowering agents that cause the accumulation of glucose in the liver as glycogen. Glycogen metabolism has implications in
Publikováno v:
Egészségtudomány. 65:21-21
Publikováno v:
RSC Advances. 6:94787-94794
The synthesis of 4(5)-aryl-2-(β-D-glucopyranosyl)-imidazoles, the currently most efficient glucose derived inhibitors of glycogen phosphorylase enzymes was amended and extended by using O-perbenzylated β-D-glucopyranosyl cyanide as the starting mat